Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...

The FDA has approved the first generic GLP-1 specifically indicated for weight loss, according to a press release from Teva Pharmaceuticals. As Healio previously reported, Teva Pharmaceuticals ...

Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' cheaper generic version of Novo Nordisk's older weight-loss drug, Saxenda, the Israel-based company said on Thursday.

Israeli drugmaker Teva Pharmaceutical Industries has announced US Food and Drug Administration (FDA) approval and launch of a ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best strong buy growth stocks to buy now. On August 28, Teva ...

Teva is releasing a generic version of Novo Nordisk’s Saxenda, a liraglutide injection. Liraglutide injection is indicated for adults with obesity or overweight who also have weight related medical ...

Investing.com -- Teva Pharmaceutical Industries Ltd ADR (NYSE:TEVA) stock rose 2.7% after the company announced FDA approval and U.S. launch of its generic version of Saxenda (liraglutide injection), ...